Literature DB >> 17324721

Chronic inflammatory demyelinating polyneuropathy.

Richard A Lewis1.   

Abstract

In 1975, clinical, electrodiagnostic, and pathologic features defined chronic inflammatory demyelinating polyneuropathy (CIDP). Subsequent reports have made it clear that demyelination is a cardinal feature of teh disorder. Over the past 30 years, variants have been described and associated systemic disorders identified. There continues to be discussion, however, as to how best to define CIDP and classify the disorders that are chronic, acquired, immune mediated, and demyelinating. Understanding the disorders allows clinicians to make appropriate treatment decisions. Some disorders originally considered as variants now are shown to have characteristic features that make them distinct from CIDP. It is imperative to recognize the differences between these disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324721     DOI: 10.1016/j.ncl.2006.11.003

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  10 in total

1.  Further insight on A-wave in acute and chronic demyelinating neuropathies.

Authors:  Ferdinando Sartucci; Tommaso Bocci; Davide Borghetti; Giovanni Orlandi; Francesco Manfredonia; Luigi Murri; Fabio Giannini; Alessandro Rossi
Journal:  Neurol Sci       Date:  2010-06-18       Impact factor: 3.307

2.  Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.

Authors:  Carlo Lazzaro; Leonardo Lopiano; Dario Cocito
Journal:  Neurol Sci       Date:  2014-01-28       Impact factor: 3.307

3.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

4.  Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.

Authors:  Gord Blackhouse; Kathryn Gaebel; Feng Xie; Kaitryn Campbell; Nazila Assasi; Jean-Eric Tarride; Daria O'Reilly; Colin Chalk; Mitchell Levine; Ron Goeree
Journal:  Cost Eff Resour Alloc       Date:  2010-06-17

5.  Chronic inflammatory demyelinating polyradiculoneuropathy in a boy with systemic lupus erythematosus.

Authors:  Morel Ayala Zoilo; Benadón Eduardo; Faugier Enrique; Maldonado V M del Rocio
Journal:  Rheumatol Int       Date:  2009-06-18       Impact factor: 2.631

6.  Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.

Authors:  Kathryn Gaebel; Gord Blackhouse; Kaitryn Campbell; Diana Robertson; Feng Xie; Nazila Assasi; Colin Chalk; Mitchell Levine; Ron Goeree
Journal:  Open Med       Date:  2010-08-24

Review 7.  Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach.

Authors:  Melvin Berger; Jeffrey A Allen
Journal:  Muscle Nerve       Date:  2015-01-29       Impact factor: 3.217

Review 8.  Emerging Role of Neuron-Glia in Neurological Disorders: At a Glance.

Authors:  Md Mominur Rahman; Md Rezaul Islam; Md Yamin; Md Mohaimenul Islam; Md Taslim Sarker; Atkia Farzana Khan Meem; Aklima Akter; Talha Bin Emran; Simona Cavalu; Rohit Sharma
Journal:  Oxid Med Cell Longev       Date:  2022-08-22       Impact factor: 7.310

9.  Phenotype of CD4+ T cell subsets that develop following mouse facial nerve axotomy.

Authors:  Junping Xin; Derek A Wainwright; Craig J Serpe; Virginia M Sanders; Kathryn J Jones
Journal:  Brain Behav Immun       Date:  2007-11-19       Impact factor: 7.217

10.  Chronic inflammatory demyelinating polyradiculoneuropathy relapse after mexiletine withdrawal in a patient with concomitant myotonia congenita: A case report on a potential treatment option.

Authors:  Simona Portaro; Fiammetta Biasini; Placido Bramanti; Antonino Naro; Rocco Salvatore Calabrò
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.